OmniAb, Inc. Common Stock OABI
i
Market dataready · fetched 2026-11-06T21:38:40.974Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-12-18
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-06T21:27:33.224803766Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-06T21:38:39.855716+00:00
OmniAb, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 3.19 | 281.1% | 49.6% | |||
| 25Δ | 3.61 | 239.5% | 41.3% | |||
| 30Δ | 4.03 | 198.0% | 33.0% | |||
| 35Δ | 4.45 | 156.4% | 24.7% | |||
| 40Δ | 4.86 | 114.9% | 16.4% | |||
| 45Δ | 5.20 | 101.3% | 12.8% | |||
| 50Δ | 5.50 | 101.1% | 11.4% | |||
| 55Δ | 5.79 | 101.0% | 10.0% | |||
| 60Δ | 6.09 | 100.8% | 8.6% | |||
| 65Δ | 4.67 | 130.3% | 15.3% | 6.38 | 100.6% | 7.1% |
| 70Δ | 4.34 | 128.1% | 13.1% | 6.68 | 100.5% | 5.7% |
| 75Δ | 4.01 | 125.9% | 10.8% | 6.98 | 100.3% | 4.3% |
| 80Δ | 3.68 | 123.7% | 8.6% | 7.27 | 100.1% | 2.9% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.19
- IV
- 281.1%
- B/E move
- 49.6%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.61
- IV
- 239.5%
- B/E move
- 41.3%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.03
- IV
- 198.0%
- B/E move
- 33.0%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.45
- IV
- 156.4%
- B/E move
- 24.7%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.86
- IV
- 114.9%
- B/E move
- 16.4%
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.20
- IV
- 101.3%
- B/E move
- 12.8%
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.50
- IV
- 101.1%
- B/E move
- 11.4%
55Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.79
- IV
- 101.0%
- B/E move
- 10.0%
60Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.09
- IV
- 100.8%
- B/E move
- 8.6%
65Δ
- Pseudo strike
- 4.67
- IV
- 130.3%
- B/E move
- 15.3%
- Pseudo strike
- 6.38
- IV
- 100.6%
- B/E move
- 7.1%
70Δ
- Pseudo strike
- 4.34
- IV
- 128.1%
- B/E move
- 13.1%
- Pseudo strike
- 6.68
- IV
- 100.5%
- B/E move
- 5.7%
75Δ
- Pseudo strike
- 4.01
- IV
- 125.9%
- B/E move
- 10.8%
- Pseudo strike
- 6.98
- IV
- 100.3%
- B/E move
- 4.3%
80Δ
- Pseudo strike
- 3.68
- IV
- 123.7%
- B/E move
- 8.6%
- Pseudo strike
- 7.27
- IV
- 100.1%
- B/E move
- 2.9%
Options history
Table
| Date | IV (%) |
|---|---|
| 106.21% | |
| 120.35% | |
| 113.58% |
Biotechnology
OBIO
Orchestra BioMed Holdings, Inc. is a therapeutic device company that develops therapeutic treatments and products for cardiovascular diseases. The company is headquartered in New…
More →OCGN
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the development of gene therapies to cure diseases of blindness. The company is headquartered in Malvern,…
More →OCS
Oculis Holding AG, a biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company is headquartered in Zug,…
More →OCUL
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its…
More →OLMA
Description unavailable
More →OMER
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and markets protein and small molecule therapies, and orphan indications targeting…
More →